The FDA’s Center for Drug Evaluation and Research has launched its pilot to publicly release clinical study report (CSR) data from pivotal clinical trials as part of a greater push for agency transparency in the approval of new drugs.
The FDA’s Center for Drug Evaluation and Research (CDER) has launched its pilot to publicly release data from pivotal clinical trials as part of a greater push for agency transparency in the approval of new drugs. The first product to have its pivotal trial information released is Janssen Biotech’s apalutamide (Erleada), an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer, which was approved by the FDA in February 2018.
The pilot will include up to a total of 9 recently submitted new drug applications. If these applications are approved, CDER will release portions of the clinical study reports (CSRs) from the sponsors’ New Drug Applications. The CSR information—which comprises the study report’s body, the study’s protocol and amendments, and the statistical analysis plan—will be included in the information posted at the drug’s entry at the agency’s Drugs@FDA website.
In an FDA Voice blog post announcing publication of apalutamide’s data, Janet Woodcock, MD, director of CDER, wrote, “Many factors are involved in weighing the benefits a drug can provide against the risks associated with its use. To that end, after we approve a new drug, we also want to make sure the scientific community and the public can understand why we approved it. This can help inform future drug development and, in turn, may facilitate the approval of additional safe and effective medicines.”
With apalutamide in particular, Woodcock added, “It’s a novel drug and we believe the CSR information, together with the FDA review, label, and other supporting documents, will facilitate a deeper understanding of how we reached our approval decision.”
The transparency program was first announced in January 2018 by FDA Commissioner Scott Gottlieb, MD, who said that, once the pilot program is complete, the agency will seek public feedback through a Federal Register notice and a docket for public comments.
In addition to helping the public better understand the rationale for drug approval, the pilot program is intended to help with global regulatory alignment, as the European Medicines Agency (EMA) is working on a similar task to make approvals more accessible and easy to understand.
The EMA’s initiative entered into force in January 2015, and the agency publishes clinical data submitted by manufactures in support of their requests for marketing authorization. These data, reviewed by the Committee for Medicinal Products for Human Use, include a clinical overview, a clinical summary, study reports on individual clinical studies, and 3 appendices, including study protocol, a sample case report form used to collect data on individual patients, and documentation of statistical methods used to analyze study data.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.